Monte Rosa Therapeutics (GLUE) closed at $10.57 on November 6, 2026, up 3.1% from the previous close, on volume of 810,765 shares (30-day average 1,479,144).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Wedbush Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)
TipRanks (Fri, 6-Nov 9:56 AM ET)
Monte Rosa Therapeutics (GLUE) Gets a Buy from Wells Fargo
TipRanks (Fri, 6-Nov 9:15 AM ET)
Guggenheim Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)
TipRanks (Fri, 6-Nov 9:15 AM ET)
TipRanks (Fri, 6-Nov 9:01 AM ET)
Monte Rosa Therapeutics reports Q3 results
Seeking Alpha News (Thu, 5-Nov 7:28 AM ET)
Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Globe Newswire (Wed, 28-Oct 7:00 AM ET)
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:01 PM ET)
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Monte Rosa Therapeutics trades on the NASDAQ stock market under the symbol GLUE.
As of November 6, 2026, GLUE stock price climbed to $10.57 with 810,765 million shares trading.
GLUE has a beta of 1.91, meaning it tends to be more sensitive to market movements. GLUE has a correlation of 0.08 to the broad based SPY ETF.
GLUE has a market cap of $901.76 million. This is considered a Small Cap stock.
Last quarter Monte Rosa Therapeutics reported $54 million in Revenue and $.03 earnings per share. This beat revenue expectation by $18 million and exceeded earnings estimates by $.21.
In the last 3 years, GLUE traded as high as $25.77 and as low as $2.91.
The top ETF exchange traded funds that GLUE belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
GLUE has underperformed the market in the last year with a return of -18.8%, while the SPY ETF gained +10.8%. In the last 3 month period, GLUE fell short of the market, returning -32.7%, while SPY returned -4.1%. However, in the most recent 2 weeks GLUE has outperformed the stock market by returning -2.5%, while SPY returned -3.2%.
GLUE support price is $9.86 and resistance is $10.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLUE shares will trade within this expected range on the day.
